182 related articles for article (PubMed ID: 35039049)
1. A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study.
Choi BC; Zhou C; Ye H; Sun Y; Zhong Y; Gong F; Sini I; Abramova N; Longobardi S; Hickey M; D'Hooghe T
Reprod Biol Endocrinol; 2022 Jan; 20(1):15. PubMed ID: 35039049
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
[TBL] [Abstract][Full Text] [Related]
4. Fine-tuning the dose of recombinant human follicle-stimulating hormone alfa to individualize treatment in ovulation induction and ovarian stimulation cycles: a real-world database analysis.
Martini AE; Beall S; Ball GD; Hayward B; D'Hooghe T; Mahony MC; Collares F; Catherino AB
Front Endocrinol (Lausanne); 2023; 14():1195632. PubMed ID: 37727455
[TBL] [Abstract][Full Text] [Related]
5. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
[TBL] [Abstract][Full Text] [Related]
7. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
Frydman R; Howles CM; Truong F
Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.
Bühler KF; Fischer R; Verpillat P; Allignol A; Guedes S; Boutmy E; Bilger W; Richter E; D'Hooghe T
Reprod Biol Endocrinol; 2021 Jun; 19(1):90. PubMed ID: 34134695
[TBL] [Abstract][Full Text] [Related]
10. The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.
Velthuis E; Hubbard J; Longobardi S; D'Hooghe T
Adv Ther; 2020 Dec; 37(12):4831-4847. PubMed ID: 33058045
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.
Lehert P; Kolibianakis EM; Venetis CA; Schertz J; Saunders H; Arriagada P; Copt S; Tarlatzis B
Reprod Biol Endocrinol; 2014 Feb; 12():17. PubMed ID: 24555766
[TBL] [Abstract][Full Text] [Related]
12. Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction.
Serour GI; Aboulghar M; Al Bahar A; Hugues JN; Esmat K
Reprod Biol Endocrinol; 2014 Jun; 12():52. PubMed ID: 24942155
[TBL] [Abstract][Full Text] [Related]
13. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jan; 14():1. PubMed ID: 26733057
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Reprod Biomed Online; 2024 Jun; 48(6):103725. PubMed ID: 38593745
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.
Bergh C; Howles CM; Borg K; Hamberger L; Josefsson B; Nilsson L; Wikland M
Hum Reprod; 1997 Oct; 12(10):2133-9. PubMed ID: 9402268
[TBL] [Abstract][Full Text] [Related]
16. Individualized recombinant human follicle-stimulating hormone dosing using the CONSORT calculator in assisted reproductive technology: a large, multicenter, observational study of routine clinical practice.
Naether OG; Tandler-Schneider A; Bilger W
Drug Healthc Patient Saf; 2015; 7():69-76. PubMed ID: 25926756
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis.
Lehert P; Schertz JC; Ezcurra D
Reprod Biol Endocrinol; 2010 Sep; 8():112. PubMed ID: 20846363
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
Chua SJ; Mol BW; Longobardi S; Orvieto R; Venetis CA; Lispi M; Storr A; D'Hooghe T
Reprod Biol Endocrinol; 2021 Apr; 19(1):51. PubMed ID: 33794909
[TBL] [Abstract][Full Text] [Related]
19. Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017).
Fatemi H; Bilger W; Denis D; Griesinger G; La Marca A; Longobardi S; Mahony M; Yin X; D'Hooghe T
Reprod Biol Endocrinol; 2021 May; 19(1):68. PubMed ID: 33975610
[TBL] [Abstract][Full Text] [Related]
20. Comfort, ease of use and practicality of the pen injector for follitropin α for assisted reproduction: an observational post-marketing study in Egypt.
Yehia M; El-Khayat W; Kortam A; Mowafy AH; Aziz Khalifa AA; Awad A; Khattab S
Curr Med Res Opin; 2013 Nov; 29(11):1429-34. PubMed ID: 23899053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
